Pulmonary Tetrapeptide Bioregulator
Bronchogen is a lung-specific tetrapeptide bioregulator that restores the gene expression of bronchial tissue toward healthier patterns, improving mucociliary clearance, reducing airway inflammation, and measurably increasing lung function in aged and compromised populations. Its short 10-day cycle protocol produces lasting improvements in breathing quality that persist well beyond the active treatment period.
Product
Research shows
Practical product identifiers and format details for professional review.
Content
30 mg
Format
Injectable
Composition
10 mg/ml per ml
Bronchogen binds to regulatory regions of bronchial epithelial cell DNA and promotes the expression of genes associated with mucociliary clearance, goblet cell regulation, and bronchial smooth muscle tone normalisation. It reduces aberrant inflammatory gene expression in chronically irritated bronchial tissue, promotes the regeneration of ciliated epithelial cells responsible for airway self-cleaning, and normalises bronchial mucous secretion patterns. Research has shown improvements in FEV1, exercise tolerance, and subjective respiratory quality in aged populations after repeated Bronchogen courses.
Based on published research and preclinical data. All benefits are documented under research-grade conditions.
Bronchogen is designed specifically for bronchial tissue, using the Khavinson bioregulator principle: a short peptide whose amino acid sequence provides binding specificity for DNA regulatory regions in the target organ. This tissue specificity distinguishes it from general anti-inflammatory approaches.
The cilia-lined bronchial epithelium responsible for clearing mucus and pathogens declines in function with age and after respiratory infections. Bronchogen promotes the regeneration of ciliated cells and normalises their gene expression, improving the self-cleaning capacity of the airways.
By normalising gene expression in chronically inflamed bronchial tissue, Bronchogen reduces aberrant cytokine production and inflammatory signalling in the bronchial mucosa: relevant for post-infectious airway inflammation, COPD, and chronic airway irritation.
Persistent bronchial tissue damage and impaired mucociliary function are reported in long-COVID and post-viral respiratory conditions. Bronchogen's ability to normalise bronchial cell gene expression makes it of specific interest for recovery from respiratory infections with residual lung dysfunction.
Clinical research from the Khavinson Institute documents improvements in FEV1 (forced expiratory volume), exercise tolerance, and subjective respiratory quality in aged and compromised populations receiving repeated Bronchogen courses.
Like all Khavinson bioregulators, Bronchogen is administered in short 10-day courses followed by multi-month breaks. This intermittent stimulation protocol is consistent with its role as a gene expression normaliser rather than a continuous pharmacological agent.
Explore selected publications on Bronchogen, with links to the original sources.
5 publications from the research library.
Evidence type
Publication and key finding
Source
Evidence type
Preclinical study
Direct Bronchogen evidence
Publication and key finding
The study reports that bronchogen increased the melting temperature of DNA from calf thymus and mouse liver by 3.1°C in a narrow range of r (molar ratio of bronchogen/DNA b.p., 0.01-0.055).
Bulletin of experimental biology and medicine
Evidence type
Preclinical study
Research relevant to Bronchogen
Publication and key finding
The study reports that following the course of peptide treatment the decreased activity of neutrophilic inflammation with the normalization of cellular composition and profile of pro-inflammatory cytokines and enzymes in the bronchoalveolar space was observed.
Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova
Evidence type
Preclinical study
Research relevant to Bronchogen
Publication and key finding
The study reports that enhanced production of secretory IgA, a local immunity marker, attested to normalization of functional activity of bronchial epithelium, while normalization of cell composition and profile of proinflammatory cytokines in the bronchoalveolar space reflected reduction of neutrophilic inflammation.
Bulletin of experimental biology and medicine
Evidence type
Preclinical study
Research relevant to Bronchogen
Publication and key finding
The study reports that the peptide effective concentration of 0.05 ng/ml showed a stimulating effect in appropriate tissue cultures as compared to the control explants in all groups of rats.
Advances in gerontology = Uspekhi gerontologii
Evidence type
Laboratory study
Research relevant to Bronchogen
Publication and key finding
The study reports that reduced expression of these differentiation markers was detected in late-passage (aging) cultures.
Bulletin of experimental biology and medicine
Labbieux pens are designed for 30 to 31 administrations of 10 clicks. With daily use, this corresponds to approximately one month. We recommend starting with 5 clicks and building up to 10 clicks per administration. More sensitive people may use fewer clicks.
Before using our pens, consult the manual.
Bronchogen has an excellent safety profile from decades of clinical research. As a tetrapeptide bioregulator with organ-specific DNA binding activity, it is highly targeted and produces minimal off-target effects. Injection site reactions are the most commonly reported adverse effect. No systemic toxicity, immune dysfunction, or hormonal effects have been documented. Its intermittent cycling structure (10 days on, months off) ensures limited cumulative exposure. As with all immunomodulatory peptides, theoretical caution exists for individuals with active autoimmune conditions affecting the lungs.
This public COA documents one selected production batch and is updated annually. It is not the COA for our latest available batch. Every batch has its own documentation, and partners can request the latest batch COA from our team.
Other products from the same range
